Jamie Bates
About Jamie Bates
I have 10 years of experience in Biotech spanning oncology and fibrosis at Gilead Sciences. I am currently a Director of Oncology, leading a new group focused on targeting tumor stromal and myeloid biology. After obtaining a PhD from Berkeley and completing a post-doc at Stanford, I joined the oncology department at Gilead Sciences, where I led the biology for an early stage program and coordinated drafting of the pharmacology reports for a successful IND. I then moved into the field of Non-alcoholic Steatohepatitis (NASH), where I helped to build our fibrosis expertise, led evaluation of potential combination partners for early stage clinical assets, and supported evaluation of new targets and BD opportunities. Managing a group of about 7 scientists, I rose to the Director level, leading both small and large molecule projects, working cross-functionally to make key decisions driving the teams toward IND, and leading non-clinical teams supporting clinical-stage assets. In 2020, I moved back to Gilead oncology to help drive our tumor microenvironment efforts, reflecting a marriage of my two areas of expertise; oncology and fibrosis. My goal is to develop drugs that will complement current immunotherapy approaches, to broaden the response to such therapies.